Patent ID: 8333968
Filing Date: 2012-12-18
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A method of treating inflammation in a patient in need thereof, comprising administering an effective amount of an antagonist of IL-23 and IL-17A or IL-17F to the patient, wherein the antagonist comprises an anti-IL-23 antibody or fragment thereof, which binds the p19 subunit of IL-23, and comprises a heavy chain variable region polypeptide as shown in SEQ ID NO:268 and a light chain variable region polypeptide as shown in SEQ ID NO:266; and a cross-reactive antibody or fragment thereof, which binds IL-17A or IL-17F, and comprises the CDRs of an antibody selected from the group consisting of: a) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7987; b) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7988; and c) the antibody produced by the hybridoma of ATCC Patent Deposit Designation PTA-7989.